SAN CLEMENTE, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Preclinical testing has begun on the novel glaucoma treatment recently licensed by Advanced Refractive Technologies (OTC Bulletin Board: ARFR - News). This first step in clinical trials will assess the safety and efficacy of the compound before the initiation of human trials. The in vitro portion of this testing will require approximately six months to complete at which time the in vivo testing will begin. After six months of this in vivo testing, the Phase One human trials should be underway.
